TLSIW · TriSalus Life Sciences Inc. Warrant
View on chartInsiders & Stakes
| Mary T. Szela CEO and President | ▼ Sell | Tax Withholding | 1,074,990 Shares held | 10/5/2026 | View profile |
| Cox Bryan F. Chief of Research | ▼ Sell | Open Market | 162,805 Shares held | 10/5/2026 | View profile |
| Marshak Richard Chief Commercial Officer | ▼ Sell | Open Market | 127,994 Shares held | 10/5/2026 | View profile |
| Stevens Jennifer Chief Regulatory Officer | ▼ Sell | Open Market | 123,794 Shares held | 10/5/2026 | View profile |
Transaction History
| Cox Bryan F. | ▼ Sell | Open Market | 296 | $1K | 10/5/2026 |
| Marshak Richard | ▼ Sell | Open Market | 325 | $1K | 10/5/2026 |
| Stevens Jennifer | ▼ Sell | Open Market | 316 | $1K | 10/5/2026 |
| Mary T. Szela | ▼ Sell | Tax Withholding | 2,693 | $12K | 10/5/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
TriSalus Warrant Gains After FDA Clears TriNav Advance
TriSalus Life Sciences received FDA clearance for its TriNav Advance device, a move that strengthens its portfolio for liver embolization. This regulatory approval contributed to a 15.6% rise in the company's shares. The positive news provides context for the warrant's recent price action, which remains within its 52-week trading range.
TriSalus Warrant Gains After FDA Clears TriNav Advance. TriSalus Life Sciences received FDA clearance for its TriNav Advance device, a move that strengthens its portfolio for liver embolization. This regulatory approval contributed to a 15.6% rise in the company's shares. The positive news provides context for the warrant's recent price action, which remains within its 52-week trading range.